These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 2184514)
81. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. Sobel JD; Wiesenfeld HC; Martens M; Danna P; Hooton TM; Rompalo A; Sperling M; Livengood C; Horowitz B; Von Thron J; Edwards L; Panzer H; Chu TC N Engl J Med; 2004 Aug; 351(9):876-83. PubMed ID: 15329425 [TBL] [Abstract][Full Text] [Related]
82. Addisonian crisis in a liver transplant patient due to fluconazole withdrawal. Tiao GM; Martin J; Weber FL; Cohen RM; Hanto DW Clin Transplant; 1999 Feb; 13(1 Pt 1):62-4. PubMed ID: 10081637 [TBL] [Abstract][Full Text] [Related]
83. Amphotericin B formulations: a comparative review of efficacy and toxicity. Hamill RJ Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001 [TBL] [Abstract][Full Text] [Related]
84. The Efficacy and Safety of Antifungal Agents for Managing Oral Candidiasis in Oncologic Patients: A Systematic Review With Network Meta-Analysis. de Lima AF; Fagundes VL; Marques NB; Borba HL; Domingos EL; Tonin FS; Pontarolo R Cureus; 2024 Sep; 16(9):e69340. PubMed ID: 39398751 [TBL] [Abstract][Full Text] [Related]
85. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Gøtzsche PC; Johansen HK Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD000026. PubMed ID: 25188768 [TBL] [Abstract][Full Text] [Related]
86. Interventions for preventing oral candidiasis for patients with cancer receiving treatment. Clarkson JE; Worthington HV; Eden OB Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD003807. PubMed ID: 17253497 [TBL] [Abstract][Full Text] [Related]
87. Fungal infections in patients with neutropenia: challenges in prophylaxis and treatment. Herbrecht R; Neuville S; Letscher-Bru V; Natarajan-Amé S; Lortholary O Drugs Aging; 2000 Nov; 17(5):339-51. PubMed ID: 11190415 [TBL] [Abstract][Full Text] [Related]
88. Penetration of oral fluconazole into gynecological tissues. Mikamo H; Kawazoe K; Sato Y; Izumi K; Ito T; Ito K; Tamaya T Antimicrob Agents Chemother; 1999 Jan; 43(1):148-51. PubMed ID: 9869580 [TBL] [Abstract][Full Text] [Related]
89. Antifungal prophylaxis during neutropenia and immunodeficiency. Lortholary O; Dupont B Clin Microbiol Rev; 1997 Jul; 10(3):477-504. PubMed ID: 9227863 [TBL] [Abstract][Full Text] [Related]
90. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Goa KL; Barradell LB Drugs; 1995 Oct; 50(4):658-90. PubMed ID: 8536553 [TBL] [Abstract][Full Text] [Related]
91. Clinical and mycological evaluation of fluconazole in the secondary prophylaxis of esophageal candidiasis in AIDS patients. An open, multicenter study. Agresti MG; de Bernardis F; Mondello F; Bellocco R; Carosi GP; Caputo RM; Milazzo F; Chiodo F; Giannini V; Minoli L Eur J Epidemiol; 1994 Feb; 10(1):17-22. PubMed ID: 7957784 [TBL] [Abstract][Full Text] [Related]
92. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group. Ninane J Eur J Clin Microbiol Infect Dis; 1994 Apr; 13(4):330-7. PubMed ID: 7794307 [TBL] [Abstract][Full Text] [Related]
93. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center study. Egger T; Gratwohl A; Tichelli A; Uhr M; Stebler Gysi C; Passweg J; Pless M; Wernli M; Buser U; Wuhrmann J Support Care Cancer; 1995 Mar; 3(2):139-46. PubMed ID: 7773582 [TBL] [Abstract][Full Text] [Related]
94. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Akova M; Akalin HE; Uzun O; Gür D Eur J Clin Microbiol Infect Dis; 1991 Jul; 10(7):598-9. PubMed ID: 1915408 [No Abstract] [Full Text] [Related]